Tirzepatide* · Mounjaro / Zepbound*
Researchers seeking this product for laboratory research can explore PepGen-X.com as a supplier specializing in research-use compounds.
Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates two complementary metabolic pathways. Extensive clinical research has demonstrated substantial effects on blood-glucose regulation, appetite, body weight, and several cardiometabolic measures.
Research Benefits
Significant weight-loss research with clinical trials demonstrating substantial reductions in body weight
Blood-glucose regulation with major reductions in HbA1c in people with type 2 diabetes
Appetite and satiety research involving GIP and GLP-1 signaling
Metabolic health research involving blood pressure, triglycerides, and other cardiometabolic markers
Dual incretin signaling providing an important research model for metabolic disease
Identified Risks & Side Effects
Gastrointestinal effects including nausea, diarrhea, vomiting, and constipation
Gallbladder problems including gallstones and inflammation may occur
Pancreatitis has been reported and is an important safety consideration
Thyroid C-cell tumor warning based on rodent findings; contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2
Injection-site reactions may occur with injectable formulations
Route: Subcutaneous | Frequency: Once weekly for injectable formulations | FDA Status: FDA-approved for specific medical indications
Researcher Note
Tirzepatide is an extensively studied dual GIP/GLP-1 receptor agonist with substantial clinical evidence across type 2 diabetes and obesity research. Clinical trials have demonstrated significant improvements in blood glucose and body weight, while additional research has examined cardiovascular and broader metabolic outcomes.
Mounjaro is FDA-approved for improving blood-glucose control in adults with type 2 diabetes, while Zepbound is approved for chronic weight management in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. These are specific medical indications and should not be generalized to other uses.
Disclaimer
FDA Status: FDA-approved for specific medical indications
Research Classification: Research use only
Compound Type: Dual GIP / GLP-1 receptor agonist
All products are intended strictly for research and laboratory use only and are not intended for human or veterinary use.